跳至主要内容
临床试验/NCT00126464
NCT00126464Unknown不适用

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant (Faslodex) in Breast Ductal Carcinoma (DCIS)

Cedars-Sinai Medical Center2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2004年11月最近更新:
适应症
相关药物

试验速览

阶段
不适用
入组人数
100
试验地点
2
主要终点
Molecular markers of the estrogen pathway as measured by immunohistochemistry at 3 weeks

研究概览

简要总结

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving fulvestrant or tamoxifen before surgery may be an effective treatment for breast cancer.

PURPOSE: This randomized clinical trial is studying how well giving fulvestrant or tamoxifen works in treating postmenopausal women who are undergoing surgery for ductal carcinoma in situ of the breast.

详细描述

OBJECTIVES:

Primary

  • Determine, preliminarily, the efficacy of neoadjuvant fulvestrant, in terms of molecular changes in markers of the estrogen pathway, cell proliferation and apoptosis, and the epidermal growth factor pathway, in postmenopausal women with newly diagnosed ductal carcinoma in situ of the breast.

Secondary

  • Determine the toxicity profile of fulvestrant in these patients.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment

入排标准

性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Molecular markers of the estrogen pathway as measured by immunohistochemistry at 3 weeks

次要结局

  • Mammographic breast density as measured by the Madena method at 3 weeks

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验